Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants

NCT05556226 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

ABBV-154

Interventions

DRUG: ABBV-154 Dose Formulation A
DRUG: ABBV-154 Dose Formulation B

Sponsor

AbbVie